ANG
- Carries the full investment and finances, builds and operates both plants
- Selects the technology licensor and EPC contractor
- Leads technology transfer, training and GMP certification
Live · Phase 1: Secondary Packaging & Serialization
From the cartonto the molecule
Iraq's first integrated insulin and human vaccine manufacturing platform, developed in partnership with SDI Samarra. Three phases take us from secondary packaging to aseptic fill & finish, then to drug substance manufacturing with a global technology licensor.
- Secondary packagingLive
- Drug productNext
- Drug substanceTarget
20,580,000insulin vials & pens a year at full capacity
15,642,751vaccine & immunoglobulin units a year
28,750m² of plant sites on the SDI campus
54months from site handover to full production
25years of PPP term after commissioning
Who we are
A public–private partnership with a national mandate
Ard Nabaa Al-Ghadeer (ANG) is a Baghdad-based Iraqi group active in trading, contracting, investment and development. Its pharmaceutical division leads the localization of strategic biologics in Iraq, in partnership with the State Company for Drugs Industry and Medical Appliances (SDI) of the Ministry of Industry and Minerals, under the Iraqi Investment Law.
SDI Samarra
- Provides the Nineveh sites free of charge for the full term
- Secures economic protection and market access
- Brings decades of Iraqi pharmaceutical manufacturing experience
Ministries of Health and Industry
- Insulin: capacity sized to Ministry of Health demand
- Vaccines: Ministry of Health as sole buyer under an off-take agreement
- Vaccines: sovereign guarantee and national exclusivity, per preliminary government understandings
Approvals secured Ministry of Industry and Minerals SDI Board of Directors Ministry of Health (vaccines) Vaccines project formally awarded to ANG
Vision & direction
A self-reliant Iraq where every patient can count on insulin and vaccines made at home to world standards.
Mission
To bring proven biopharmaceutical technology to Iraq through long-term partnerships with global licensors, to build and operate GMP plants in Nineveh, to develop Iraqi talent, and to supply the Ministry of Health with quality medicines below today's import prices.
Our promise to partners
Transparent governance, a phased model that protects every party's investment, and a site, a market and a mandate that are ready now.
Quality first
cGMP and WHO-aligned practice in every room, record and release.
Patients at the centre
Reliable supply for people living with diabetes and for every child's immunization schedule.
Partnership
Lasting relationships with licensors, contractors and our public partner.
Local capability
Genuine technology transfer and Iraqi talent at every level of the plant.
Responsibility
Biosafety, clean effluent and energy efficiency by design.
Made in Iraq. Held to global standards.Health security is national security.Medicines Iraq can count on.Your technology. Our commitment. Iraq's future.Made in Iraq. Held to global standards.Health security is national security.Medicines Iraq can count on.Your technology. Our commitment. Iraq's future.
Strategic directions
Five commitments behind every decision
Localize
Replace imports
Iraq imports all of its insulin today. We will make it at home and keep hard currency in the economy.
Transfer
Own the know-how
End-to-end technology transfer, from master cell bank to QC release, with Iraqi teams trained at every step.
Secure
Guarantee supply
Ministry of Health contracts, a validated 2–8 °C cold chain and GS1 serialization against falsified medicines.
Comply
Meet global standards
cGMP, WHO GMP, ICH Q9 and Q10, ISO 14644 cleanrooms and a full validation master plan.
Sustain
Protect people and environment
ESIA-based design, biological effluent decontamination and treatment of every waste stream.
Phased localization model
We build from the outside in
Each phase adds a deeper layer of manufacturing value. Revenue starts early with secondary packaging, while the licensor's technology arrives in two steps: drug product first, then drug substance.
01Live now
Secondary Packaging & Serialization
Months 0–6 · fast-track revenue
Imported finished insulin and vaccines (vials, cartridges and pens) are packed in Nineveh against secured Ministry of Health supply contracts, using 50% or more of line capacity.
- Cartoning and final packing
- Labelling and leaflet insertion
- GS1 2D DataMatrix serialization
- 2–8 °C cold-chain warehousing
02After licensor agreement
Drug Product: Formulation, Aseptic Fill & Finish
Up to month 24
The licensor's bulk drug substance is formulated and aseptically filled under Grade A conditions, while basic design, FEED, detailed design and EPC run in parallel.
- Aseptic vial and cartridge filling
- Prefilled pen assembly
- Isolators or RABS with 100% automated visual inspection
- Operator training and process performance qualification
03Full technology transfer
Drug Substance: API & Antigen Manufacturing
Months 24–54
The complete product is made in Iraq: recombinant insulin API through fermentation and purification, plus vaccine antigen production, with QC release on site.
- Master and working cell banks (MCB / WCB)
- Upstream fermentation and downstream purification
- Vaccine antigen production
- 700 kg a year of crystalline insulin
Critical milestone: technology licensor and EPC contractorShortlisted insulin and vaccine licensors are under evaluation and negotiation. The selected partner will define the portfolio, capacity and process for Phases 2 and 3.
In negotiation Indicative timeline from site handover. Phase durations follow the insulin plan (24 + 30 months); the vaccines plant follows the same 54-month frame.
Manufacturing platforms
Two strategic plants. One campus.
Both plants are located on SDI land in Tel Kaif District, Nineveh Governorate. Portfolios and capacities come from our conceptual studies and will be finalized with the technology licensor.
Plant 01 · First of its kind in Iraq
Insulin Plant
Recombinant human insulin and insulin analogues in vials and prefilled pens for the Ministry of Health, public hospitals and the private market, with export potential.
- Site area
- 16,250 m²
- Crystalline insulin
- 700 kg a year
- Finished units a year
- 20,580,000
- Investment
- 100% financed by ANG
- Delivery
- 54 months
- Environmental study
- ESIA available for site
| Product | Units a year |
|---|---|
| Rapid-acting insulinVial, 10 mL | 5,310,00025.8% |
| Long-acting insulinVial, 10 mL | 5,280,00025.7% |
| Intermediate-acting insulinVial, 10 mL | 9,510,00046.2% |
| Insulin glarginePrefilled pen, 3 mL | 240,0001.2% |
| Insulin detemirPrefilled pen, 3 mL | 240,0001.2% |
| Total | 20,580,000 |
Process basis: recombinant DNA technology (microbial expression), from fermentation to purified API.
Plant 02 · BOOT · 25 years
Human Vaccines Plant
Routine immunization and seasonal vaccines for Iraq's national programme, with the Ministry of Health as sole buyer under an off-take agreement.
- Site area
- 12,500 m²
- Proposed capacity
- 15,642,751
- Buyer
- Ministry of Health off-take
- Investment
- 100% financed by ANG
- Delivery
- 54 months
- Structure
- Build-Own-Operate-Transfer (BOOT)
| Product | Units a year |
|---|---|
| Seasonal influenza vaccine (Northern Hemisphere)Single-dose prefilled syringe | 7,058,82445.1% |
| DTaP-IPVDiphtheria, tetanus, acellular pertussis and polio · vial | 2,222,22214.2% |
| Pentavalent DTwP-Hib-HepBVial | 2,131,43913.6% |
| Tetanus immunoglobulinSingle-dose injection | 1,623,81610.4% |
| Inactivated poliovirus vaccine (IPV)Single-dose vial | 1,463,5939.4% |
| MMR (measles, mumps, rubella)10-dose and single-dose vials | 1,142,8577.3% |
| Total | 15,642,751 |
Capacity based on a preliminary market survey, to be scaled with the licensor to Iraq's requirements.
Market opportunity
A large market served entirely by imports
Iraq has no domestic insulin producer. The Ministry of Health imports about 30% of demand and the private sector the remaining 70%. Demand grows by about 5% a year.
Source: ANG insulin feasibility study (vials and pens a year).
100%of Iraq's insulin is imported today
200+direct and indirect jobs from the insulin plant
80%Iraqi workforce in the operating phase
1national buyer for vaccines under off-take
100%of the capital investment carried by ANG
6vaccine and immunoglobulin products in the first portfolio
Technology partnering
Bring your technology. We bring the site, the market and the mandate.
We are selecting technology licensors for insulin and for human vaccines, and the EPC contractor to deliver both plants. We invite manufacturers with proven, approved products and a commitment to full technology transfer.
Status: evaluation and negotiation in progress. Expressions of interest are open for insulin licensing, vaccine licensing, finished-product and bulk supply, and EPC.
What ANG bringsValue to you
- Fully financed by ANGANG carries 100% of the capital investment for both plants, from construction to commissioning and operation.
- Market access from day oneYour finished product reaches Iraqi patients through our Phase 1 packaging line while the plant is being built.
- Government backingMinisterial approvals secured, SDI as public partner and Ministry of Health off-take for vaccines.
- A site ready to build28,750 m² on the SDI Nineveh campus, provided free for the contract term, with the ESIA completed for the insulin site.
- A long-term horizon25-year agreements and a phased model that scales from finished product to bulk to full process.
- Your brand on the packLicensor trademarks can be carried on products made in the plant, alongside the national brand.
What we are looking forFrom you
- Proven productsInsulin or vaccines approved by a stringent regulatory authority (SRA) or prequalified by WHO.
- Full technology transferCell banks, process, analytical methods and CMC dossier support for registration with the Iraqi Ministry of Health.
- Staged supplyFinished product for Phase 1, then bulk drug substance for fill & finish in Phase 2.
- Training and validationHands-on training for Iraqi teams and support through DQ, IQ, OQ, PQ and process validation.
- EPC capabilityTurnkey design and construction of cleanrooms, utilities and process lines to cGMP.
- 01IntroductionShare an expression of interest and company profile.
- 02NDA and data roomAccess to feasibility studies and project data under NDA.
- 03Proposal and due diligenceTechnical and commercial proposal, site visit and due diligence.
- 04Definitive agreementsLicensing, supply and technology transfer agreements.
Quality & facility
Designed to international GMP from the first drawing
Our technical studies define the standards for quality systems, cleanrooms, utilities, validation, biosafety, cold chain and serialization.
cGMP · WHO GMPCurrent Good Manufacturing Practice as the regulatory baseline
ICH Q10 · Q9Pharmaceutical quality system and quality risk management
ALCOA+Data integrity across paper and electronic records
ISO 14644-1Cleanroom Grades A to D, HEPA 99.97% at 0.3 µm
USP · Ph. Eur. WFIWater for injection, pure steam, Class 0 compressed air
DQ · IQ · OQ · PQValidation master plan, CIP/SIP validation, contamination control strategy
BSL-2 / BSL-3Biosafety containment and effluent decontamination
GDP · 2–8 °CTemperature-mapped storage with 24/7 monitoring
GS1 DataMatrixTrack-and-trace serialization against falsified medicines
ISO 14001 · PVEnvironmental management and pharmacovigilance
Facility unitsTypical grade
Drug substance (bulk protein) productionFermenters, homogenizers, chromatography, TFF
C / DFormulationAseptic compounding, 0.22 µm sterile filtration
B / CAseptic fill & finishWashing, depyrogenation, filling, stoppering, capping
A in BSecondary packagingLabelling, cartoning, serialization
CNCQuality control and R&DHPLC, sterility, endotoxin, bioassay, stability
QCCold chain and warehousing2–8 °C rooms, −20 °C and −80 °C cell bank storage
GDPUtilities and powerPW and WFI, pure steam, HVAC, standby generation
GEPWaste treatmentMBR and MBBR, autoclaving, biohazard incineration
EDSLocation
Nineveh, northern Iraq
The plants are planned on the SDI pharmaceutical campus in Tel Kaif District, north of Mosul, on established industrial land.
- Plant site
- SDI campus, Tel Kaif District, Nineveh Governorate
- Coordinates
- 36.49° N, 43.07° E
- Public partner
- SDI headquarters, Samarra
- ANG office
- Al-Jadriya, Baghdad
Contact
Start the conversation
Licensors, EPC contractors and investors can reach the project team directly. We respond to every qualified enquiry and share project studies under NDA.
Project directorMalih@ang.com.iq
General enquiriesinfo@ang.com.iq
Phone+964 783 636 3670
Head officeAl-Jadriya, behind Al-Atraqchi Café, Baghdad, Iraq · P.O. Box 2656
Websiteang.com.iq